Humacyte Stock
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Funding History
| November 2009 | $7.0M |
|---|---|
| September 2010 | $12.0M |
| January 2015 | $49.8M |
| October 2015 | $150M |
| August 2016 | $10.0M |
| September 2017 | $14.1M |
| March 2018 | $75.0M |
Management
Co-Founder and VP
Juliana L. Blum
CEO
Carrie Cox
COO
Theodore D. Lithgow
CMO
Alison Pilgrim
CFO
Paul Boyer
Founder & CTO
Laura E. Niklason
Press
Wall Streets Journal - Jun, 11 2018
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Humacyte or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
